ERBB2 and breast carcinoma: Standard first-line treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer is endocrine therapy in combination with a cyclin dependent kinase (CDK) 4/6 inhibitor.